Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 7
Submit an article Journal homepage
33
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Merck & Co., Inc.: analysis of patenting 1998 – 2002

Peter Norman Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK. [email protected]
Pages 1037-1044 | Published online: 02 Mar 2005

Bibliography

  • STEELE P: Merck & Co.: updated analysis of patenting with comparative data for thirty-five companies. Expert Opin. Ther. Patents (1997) 7(8):795–799.
  • ••Provides the comparison analysis for thepreceding period.
  • BURKE JF, THOMAS SM, BRADY M: Merck: the scattering of DNA sequence patents. Expert Opin. Ther. Patents (1997) 7(2):1393–1400.
  • •Indicates Merck's limited activity in gene patenting.
  • STEELE P: Drug patenting in 2001. Expert Opin. Ther: Patents(2002) 12(1):3–10.
  • •Useful overview of all the major companies' activities in 2001.
  • NORMAN P: Pfizer, Inc.: analysis of patenting 1998–2001. Expert Opin. Ther. Patents (2002) 12(5):725–732.
  • NORMAN P: GlaxoSmithKline Plc: analysis of patenting 1998-2001. Expert Opin. Ther: Patents (2002) 12(9):1407–1415.
  • NORMAN P: Merck & Co. In: Pharmaceutical Development Pipelines, the top 10 companies (Chapter SMi Publishing, UK (2002).
  • NORMAN P: Merck & Co. In: Early-Stage Pharmaceutical Development Pipelines, The Top 20 Companies (Chapter 12). SMi Publishing, UK (2002).
  • •Useful comparison highlighting how little is known about Merck's early stage pipeline.
  • CLAIBORNE CE McCAULEY JA, LIBBY BE et al.: Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13(4):697–700.
  • Current Patents: Drug patents 2001, a review of pharmaceutical patenting 1995–2001. Current Patents Ltd, London, UK (2001).
  • WILLIAMS TM: Inhibitors of protein farnesylation 1998. Expert Opin. Ther. Patents (1998) 8(5):553–569.
  • WILLIAMS TM: Inhibitors of protein prenylation 1999. Expert Opin. Ther. Patents (1999) 9(9):1263–1280.
  • MACH WATE M, HARADA S, LEU CT: Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. MM. PharmacoL (2001) 60(1):36–41.
  • SPENCE S, VETTER C, HAGMANN WK et al.: Effects of VLA-4 antagonists in rat whole embryo culture. Teratology (2002) 65(1):26–37.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.